Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
Introduction: Over 2 million adults in the United States have hepatitis C virus (HCV) infection, and it contributes to approximately 14,000 deaths a year. Eight to 12 weeks of highly effective direct-acting antiviral (DAA) treatment, which can cure ≥95% of cases, is recommended for persons with hepa...
| Publicado en: | MMWR: Morbidity & Mortality Weekly Report Vol. 71; no. 32; pp. 1011 - 1018 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Centers for Disease Control & Prevention (CDC)
8/12/2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158466660&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 158466660 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01492195 MMW jtl: MMWR: Morbidity & Mortality Weekly Report issn: 01492195 maglogo: N pubinfo: dt: 8/12/2022 vid: 71 iid: 32 pid: 1493 pub: Centers for Disease Control & Prevention (CDC) place: Atlanta, Georgia artinfo: ui: 158466660 158466660 NLM35951484 10.15585/mmwr.mm7132e1 NLM35951484 158466660 ppf: 1011 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020. aug: au: Thompson, William W. Symum, Hasan Sandul, Amy Gupta, Neil Patel, Priti Nelson, Noele Mermin, Jonathan Wester, Carolyn affil: Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC sug: subj: Hepatitis C Epidemiology Hepatitis C, Chronic Epidemiology Hepatitis C Drug Therapy Hepatitis C, Chronic Drug Therapy Aged Retrospective Design Medicaid Hepatitis Viruses Vital Signs Medicare United States Adult Antiviral Agents Therapeutic Use Checklists Aged: 65+ years Adult: 19-44 years ab: Introduction: Over 2 million adults in the United States have hepatitis C virus (HCV) infection, and it contributes to approximately 14,000 deaths a year. Eight to 12 weeks of highly effective direct-acting antiviral (DAA) treatment, which can cure ≥95% of cases, is recommended for persons with hepatitis C.Methods: Data from HealthVerity, an administrative claims and encounters database, were used to construct a cohort of adults aged 18-69 years with HCV infection diagnosed during January 30, 2019-October 31, 2020, who were continuously enrolled in insurance for ≥60 days before and ≥360 days after diagnosis (47,687). Multivariable logistic regression was used to assess the association between initiation of DAA treatment and sex, age, race, payor, and Medicaid restriction status; adjusted odds ratios (aORs) and 95% CIs were calculated.Results: The prevalence of DAA treatment initiation within 360 days of the first positive HCV RNA test result among Medicaid, Medicare, and private insurance recipients was 23%, 28%, and 35%, respectively; among those treated, 75%, 77%, and 84%, respectively, initiated treatment within 180 days of diagnosis. Adjusted odds of treatment initiation were lower among those with Medicaid (aOR = 0.54; 95% CI = 0.51-0.57) and Medicare (aOR = 0.62; 95% CI = 0.56-0.68) than among those with private insurance. After adjusting for insurance type, treatment initiation was lowest among adults aged 18-29 and 30-39 years with Medicaid or private insurance, compared with those aged 50-59 years. Among Medicaid recipients, lower odds of treatment initiation were found among persons in states with Medicaid treatment restrictions (aOR = 0.77; 95% CI = 0.74-0.81) than among those in states without restrictions, and among persons whose race was coded as Black or African American (Black) (aOR = 0.93; 95% CI = 0.88-0.99) or other race (aOR = 0.73; 95% CI = 0.62-0.88) than those whose race was coded as White.Conclusions and Implications For Public Health Practice: Few insured persons with diagnosed hepatitis C receive timely DAA treatment, and disparities in treatment exist. Unrestricted access to timely DAA treatment is critical to reducing viral hepatitis-related mortality, disparities, and transmission. Treatment saves lives, prevents transmission, and is cost saving. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|